Results 31 to 40 of about 17,703,275 (296)

Circulating adropin and vascular endothelial growth factor receptor-2 levels in age-related macular degeneration and T2DM patients—A cross-sectional study

open access: yesJournal of Family Medicine and Primary Care, 2020
Background: Macular drusen formation and angiogenesis are the two chief processes associated with age-related macular degeneration. Adropin and vascular endothelial growth factor receptor-2 (VEGFR-2) may be involved in these pathologies.
Areekulangara Neethu   +4 more
doaj   +1 more source

Discovery of New VEGFR-2 Inhibitors: Design, Synthesis, Anti-Proliferative Evaluation, Docking, and MD Simulation Studies

open access: yesMolecules, 2022
Four new nicotinamide-based derivatives were designed as antiangiogenic VEGFR-2 inhibitors. The congeners were synthesized possessing the pharmacophoric essential features to bind correctly with the VEGFR-2 active pocket.
Eslam B. Elkaeed   +10 more
doaj   +1 more source

VEGFR‐2 expression in human melanoma: Revised assessment [PDF]

open access: yesInternational Journal of Cancer, 2011
AbstractVascular endothelial growth factor (VEGF) is an angiogenic factor that also functions as an autocrine growth factor for VEGF receptor (VEGFR)‐2+ melanomas. In multiple studies, VEGFR‐2 was detected by immunostaining in 78–89% of human melanoma cells, suggesting that most patients with melanoma would benefit from anti‐VEGF therapy.
Kerrington R, Molhoek   +7 more
openaire   +2 more sources

VEGF family members : modulators of tumor angiogenesis and lymphangiogenesis [PDF]

open access: yes, 2006
Members of the vascular endothelial growth factor (VEGF) family and their receptors (VEGFR) play an essential role in the development and maintenance of the blood and lymphatic vasculature.
Kopfstein, Lucie
core   +1 more source

Functional significance of VEGFR‐2 on ovarian cancer cells [PDF]

open access: yesInternational Journal of Cancer, 2008
AbstractVascular endothelial growth factor receptor (VEGFR) has recently been discovered on ovarian cancer cells, but its functional significance is unknown and is the focus of this study. By protein analysis, A2780‐par and HeyA8 ovarian cancer cell lines expressed VEGFR‐1 and HeyA8 A2774, and SKOV3ip1 expressed VEGFR‐2. By in situ hybridization (ISH),
Whitney A, Spannuth   +14 more
openaire   +2 more sources

Biomechanical stimulation promotes blood vessel growth despite VEGFR-2 inhibition

open access: yesBMC Biology, 2023
Background Angiogenesis, or the growth of new vasculature from existing blood vessels, is widely considered a primary hallmark of cancer progression. When a tumor is small, diffusion is sufficient to receive essential nutrients; however, as the tumor ...
Bronte Miller Johnson   +6 more
doaj   +1 more source

Additional file 7 of VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody

open access: yes, 2021
Additional file 7: Figure S6. VEGFR-2 is increased in the spinal cord of mice with oxaliplatin-induced neuropathy. Representative western blot images and densitometric analysis of VEGF-R1 and VEGFR-2 expression in the lumbar section of the spinal cord of
Lorenzo Di Cesare Mannelli (600627)   +14 more
core   +1 more source

Lysine Methylation Promotes VEGFR-2 Activation and Angiogenesis [PDF]

open access: yesScience Signaling, 2013
Preventing the methylation of VEGFR-2 could attenuate pathological angiogenesis in cancer.
Edward J, Hartsough   +8 more
openaire   +2 more sources

Additional file 3 of VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody

open access: yes, 2021
Additional file 3: Figure S2. Hypersensitivity-induced by VEGF-A family members is not due to the interaction with VEGFR-2. The response to a thermal stimulus (Cold plate test) was recorded after intrathecal infusion (30 ng) of (a) VEGF165b (n=5), (b ...
Lorenzo Di Cesare Mannelli (600627)   +14 more
core   +1 more source

Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer

open access: yesCells, 2022
NSCLC treatment includes targeting of EGFR with tyrosine kinase inhibitors (TKIs) such as Erlotinib; however, resistance to TKIs is commonly acquired through T790M EGFR mutations or overexpression of vascular endothelial growth factor receptor-2 (VEGFR-2)
Chike Osude   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy